Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Serotonin transporter (SERT), encoded by the SLC6A4 gene, is a member of the solute carrier family 6 (SLC6) and serves as the primary mechanism for terminating serotonergic neurotransmission by transporting serotonin from the synaptic cleft back into the presynaptic neuron [1]. As a sodium-dependent symporter, its activity is driven by the transmembrane electrochemical gradient of sodium ions [1, 2]. SERT is a high-value therapeutic target in psychiatry, as its inhibition increases the residence time of serotonin in the synapse, thereby alleviating symptoms of major depressive disorder, anxiety, and obsessive-compulsive disorder [2]. Hyperforin, the primary antidepressant constituent of St. John's Wort, interacts with SERT through a mechanism distinct from traditional Selective Serotonin Reuptake Inhibitors (SSRIs) [3]. While SSRIs typically bind to the substrate-binding site or allosteric sites on the transporter, hyperforin acts by activating TRPC6 cation channels, leading to an influx of sodium and calcium ions [4]. This elevation of intracellular sodium reduces the driving force for SERT-mediated transport, resulting in a non-selective inhibition of serotonin, dopamine, and norepinephrine reuptake [3, 4]. Understanding this interaction is crucial for managing the significant drug-drug interaction profile of hyperforin, which also involves the induction of metabolic enzymes like CYP3A4 [3]. [1] UniProt (P31645); [2] StatPearls (Selective Serotonin Reuptake Inhibitors); [3] Müller (2003) Pharmacopsychiatry; [4] Singer et al. (1999) J Pharmacol Exp Ther.
Inhibition of serotonin reuptake from the synaptic cleft into the presynaptic neuron, thereby increasing the extracellular concentration of serotonin and enhancing serotonergic neurotransmission [2, 3]. Hyperforin specifically inhibits reuptake by elevating intracellular sodium concentrations, which reduces the transmembrane sodium gradient necessary for transporter function [4].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serotonin transporter (SERT) (SERT).